Qiagen (NYSE:QGEN) FY 2025 Conference December 02, 2025 11:15 AM ET Company ParticipantsNone - Company Representative 1Patrick Donnelly - Managing DirectorNone - Company Representative 2Daniel Wendorff - VP of Investor RelationsRoland Sackers - CFOPatrick DonnellyOkay. We can hopefully get started. Thanks for being here. I'm Patrick Donnelly, the Tools and Diagnostics analyst at Citi here. Have a nice day. Happy to continue, including Roland Sackers as CFO. Thank you guys for being here. I guess, Roland, ma ...

Qiagen (NYSE:QGEN) FY 2025 Conference December 02, 2025 11:15 AM ET Speaker1Okay. We can hopefully get started. Thanks for being here. I'm Patrick Donnelly, the Tools and Diagnostics analyst at Citi here.Speaker3Have a nice day.Speaker1Happy to continue, including Roland Sackers as CFO. Thank you guys for being here. I guess, Roland, maybe we can start. Q3 was quite eventful for you guys. Not only the results, CEO transition, acquisition, share repurchase. A lot was going on. Maybe just run us through kind ...

Core Viewpoint - The article presents a comprehensive training program focused on bioinformatics, particularly in single-cell analysis and spatial transcriptomics, aimed at enhancing research capabilities in the life sciences [56][59]. Group 1: Course Structure - The training consists of multiple sections covering Python programming, data structures, and advanced analysis techniques using various tools like scanpy and Seurat [2][6][32]. - Specific topics include spatial transcriptomics applications, data normalization, clustering, and trajectory analysis [8][12][18]. Group 2: Practical Applications - The program emphasizes hands-on experience, allowing participants to analyze real datasets and replicate findings from published research [24][25][32]. - It includes practical sessions where students can apply learned techniques to their own data, ensuring a thorough understanding of the analysis process [24][32]. Group 3: Instructor Expertise - The instructor, with extensive experience in medical artificial intelligence and bioinformatics, has guided numerous students in publishing high-impact research articles [56][59]. - The program is designed to provide personalized support, ensuring that all participants can effectively learn and apply the concepts taught [59][70]. Group 4: Community and Support - The training fosters a collaborative environment, encouraging participants to engage with each other and the instructor for ongoing support [70][72]. - There is a commitment to continuous learning, with resources available even after the course concludes, allowing for long-term skill development [72][74].

Core Insights - 10x Genomics is acquiring Scale Biosciences for $30 million in stock and cash, aiming to enhance its single-cell analysis capabilities [1][2] - The acquisition will integrate Scale's indexing and quantum barcode technologies into 10x Genomics' Chromium platform, making single-cell analysis more accessible and cost-effective for researchers [2] Financial Performance - In Q2, 10x Genomics reported total revenue of $173 million, up from $153 million year-over-year; however, core revenue decreased by 5% to $146 million after excluding a $27.3 million settlement related to a patent lawsuit [3] - Instrument revenue fell by 39% to $14.5 million, while consumables revenue slightly decreased by 1% to $122 million; spatial instrument revenue dropped by 42% to $8.8 million, but spatial consumables revenue increased by 34% to $36.4 million [3] - The company achieved a net profit of $34.5 million, or $0.28 per share, compared to a loss of $37.9 million, or $0.32 per share, in the same quarter last year [5] Regional Revenue Breakdown - Revenue from the Americas totaled $106 million, a 14% increase from $93.1 million year-over-year; EMEA revenue was $34.7 million, down 7% from $37.4 million; APAC revenue rose by 41% to $32 million from $22.7 million [4] Future Guidance - 10x Genomics expects Q3 revenue to be between $140 million and $144 million, which includes approximately $4 million in revenue from customers in China who advanced purchases due to anticipated tariff changes [6]